Guest guest Posted January 28, 2009 Report Share Posted January 28, 2009 MELBOURNE, Australia & MENLO PARK, Calif. January 19, 2009 -- ChemGenex Pharmaceuticals Limited (ASX:CXS)(NASDAQ:CXSP) announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to omacetaxine for the treatment of Myelodysplastic Syndromes (MDS). Orphan drug designation is intended to support the clinical development of new drugs in diseases affecting less than 200,000 people in the United States. The FDA often provides technical and financial assistance to expedite and optimize drug development and on approval, grants a seven year period of market exclusivity. http://www.highbeam.com/doc/1G1-192322742.html MELBOURNE, Australia & MENLO PARK, Calif. April, 1, 2008 -- ChemGenex Pharmaceuticals (ASX:CXS)(NASDAQ:CXSP) has announced interim results from its ongoing phase 2/3 trial of omacetaxine mepesuccinate (formerly known as Ceflatonin([R])) in chronic myeloid leukemia (CML) patients with the T315I mutation. The data continue to show an increase in the number of patients responding with increasing duration of response in chronic and accelerated phase patients. http://www.highbeam.com/doc/1G1-177313982.html Blessings, Lottie Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.